PMBJKs medicine sales increase 60 percent in H1 FY21

Published On 2021-02-07 03:45 GMT   |   Update On 2021-02-07 03:45 GMT

New Delhi: Medicine sales from Pradhan Mantri Bhartiya Janaushadhi Kendras (PMBJKs) increased 60 percent year-on-year during the first six months of the current fiscal amid the Covid-19 pandemic, Parliament was informed on Friday.

In a written reply to the Rajya Sabha, Union Minister for Fertilisers and Chemicals DV Sadananda Gowda said that in the ongoing financial year, Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) has already clocked sales turnover of Rs 519.34 crore till January 29, 2021, as against the target of Rs 500 crore for the entire fiscal.

Advertisement
"The sale of medicines from PMBJKs increased during the nationwide lockdown. PMBJKs have achieved 60 percent growth in sales in the first and second quarters of the FY2020-2021 as compared to the same period of the previous financial year," the minister noted.
Gowda said that in the wake of the Covid-19 pandemic, PMBJP has rendered essential services to the nation.
All PMBJKs maintained their operations regularly and made medicines available to citizens, he noted.
The minister said all manufacturing units, who were supplying medicines /surgicals for PMBJKs, were instructed to follow all Covid related safety protocols as per the guidelines of the Ministry of Health and Family Welfare and the local administration.
"Further, at the time of receipt of medicines at Bureau of Pharma PSUs of India (BPPI) warehouses, sanitisation of inward stock was done regularly. Also, all Covid-related safety protocols were followed at the stores. It was ensured that regular supply of medicines was maintained to PMBJKs, in spite of strict lockdown measures," Gowda added.


Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News